Purpose The majority of bladder cancer patients present with localized disease and are managed by transurethral resection. However, the high rate of recurrence necessitates lifetime cystoscopic surveillance. Developing a sensitive and specific urine-based test would significantly improve bladder cancer screening, detection, and surveillance. Experimental Design RNA-seq was used for biomarker discovery to directly assess the gene expression profile of exfoliated urothelial cells in urine derived from bladder cancer patients (n=13) and controls (n=10). Eight bladder cancer specific and 3 reference genes identified by RNA-seq were quantitated by qPCR in a training cohort of 102 urine samples. A diagnostic model based on the training cohort was constructed using multiple logistic regression. The model was further validated in an independent cohort of 101 urines. Results 418 genes were found to be differentially expressed between bladder cancer and controls. Validation of a subset of these genes was used to construct an equation for computing a probability of bladder cancer score (PBC) based on expression of 3-markers (ROBO1, WNT5A, and CDC42BPB). Setting PBC=0.45 as the cutoff for a positive test, urine testing using the 3-marker panel had overall 88% sensitivity and 92% specificity in the training cohort. The accuracy of the 3-marker panel in the independent validation cohort yielded an area under the curve of 0.87 and overall 83% sensitivity and 89% specificity. Conclusions Urine-based molecular diagnostics using this 3-marker signature could provide a valuable adjunct to cystoscopy and may lead to a reduction of unnecessary procedures for bladder cancer diagnosis.
Purpose and background: The magnetic resonance (MR)-only radiotherapy workflow is urged by the increasing use of MR image for the identification and delineation of tumors, while a fast generation of synthetic computer tomography (sCT) image from MR image for dose calculation remains one of the key challenges to the workflow. This study aimed to develop a neural network to generate the sCT in brain site and evaluate the dosimetry accuracy. Materials and methods: A generative adversarial network (GAN) was developed to translate T1-weighted MRI to sCT. First, the "U-net" shaped encoder-decoder network with some image translation-specific modifications was trained to generate sCT, then the discriminator network was adversarially trained to distinguish between synthetic and real CT images. We enrolled 37 brain cancer patients acquiring both CT and MRI for treatment position simulation. Twenty-seven pairs of 2D T1weighted MR images and rigidly registered CT image were used to train the GAN model, and the remaining 10 pairs were used to evaluate the model performance through the metric of mean absolute error. Furthermore, the clinical Volume Modulated Arc Therapy plan was calculated on both sCT and real CT, followed by gamma analysis and comparison of dose-volume histogram. Results: On average, only 15 s were needed to generate one sCT from one T1weighted MRI. The mean absolute error between synthetic and real CT was 60.52 AE 13.32 Housefield Unit over 5-fold cross validation. For dose distribution on sCT and CT, the average pass rates of gamma analysis using the 3%/3 mm and 2%/ 2 mm criteria were 99.76% and 97.25% over testing patients, respectively. For parameters of dose-volume histogram for both target and organs at risk, no significant differences were found between both plans. Conclusion: The GAN model can generate synthetic CT from one single MRI sequence within seconds, and a state-of-art accuracy of CT number and dosimetry was achieved.
Real-time simulation of power electronics has been recognized by the industry as an effective tool for developing power electronic devices and systems. Since there is no energy transfer during the course of the usage, real-time simulation has a lot of advantages in the process of development and experimentation. From the perspective of real-time simulation, this paper focuses on the main problems in modeling accuracy, system bandwidth and stability, limitations on communication interface and energy interface, and the cost of platform construction. Finally, we provide further research directions. Index Terms-Hardware-in-the-loop simulation, modeling and simulation of power electronics, correction method, power interface algorithm, numerical method.
We analyzed our recent stereotactic radiosurgery (SRS) experience to determine the radiographic response of intracranial metastatic melanomas to SRS. Twelve patients with 21 intracranial melanoma metastases treated with SRS were evaluated. Fifteen (72%) metastases were hemispheric, 3 (14%) were cerebellar, and 3 (14%) were in the basal ganglion or thalamus. All lesions were 2.5 cm or less in maximum diameter. Eleven patients also had whole brain external beam radiotherapy. Mean SRS dosage was 1,800 cGy to the 85% isodose surface and median dose was 1,800 cGy to the 80% isodose surface (range 1,100–3,100 cGy at the 80–95% isodose surface). Overall, 12 (57%) lesions showed decrease or stabilization of tumor volume (i.e., local control), while 9 (43%) showed enlargement. Division of metastases into small (≤1.0 cm diameter) and large (>1.0 cm diameter) tumors showed that the small tumors were more likely to regress than the large tumors (chi‐square test; P < 0.03). Only 1 of 9 (11%) large lesions regressed as opposed to 7 of 12 (58%) small lesions regressed with SRS. We conclude that SRS is suited for small melanoma brain metastases, but lesions between 1.0 and 2.5 cm in diameter, while still generally considered appropriate for SRS, may not be as responsive to SRS at currently employed dosages. Radiat. Oncol. Invest. 5:72–80, 1997. © 1997 Wiley‐Liss, Inc.
Background Volumetric modulated arc therapy (VMAT) adopted in post-mastectomy radiation therapy (PMRT) has the capacity to achieve highly conformal dose distributions. The research aims to evaluate the impact of positioning errors in the dosimetry of VMAT left-sided PMRT. Methods A total of 18 perturbations where introduced in 11 VMAT treatment plans that shifted the isocenter from its reference position of 3, 5, 10 mm in six directions. The thoracic wall and supraclavicular clinical target volumes (CTVs), the heart and the left lung dose volume histograms (DVHs) of 198 perturbed plans were calculated. The absolute differences (∆) of the mean dose (Dm) and DVH endpoints Vx and Dy (percentage volume receiving x Gy, and dose covering y% of the volume, respectively) were used to compare the dosimetry of the reference vs perturbed plans. Results Isocenter shifts in the anterior and lateral directions lead to maximum disagreement between the CTVs dosimetry of perturbed vs reference plans. Isocenter shifts of 10 mm shown a decrease of D95, D98 and Dm of 12.8, 18.0, and 2.9% respectively, for the CTVs. For 5 mm isocenter shifts, these differences decreased to 3.2, 5.2, and 0.9%, respectively, and for 3 mm shifts to 1.0, 1.7, and 0.6%, respectively. For the organs at risk (OARs), only isocenter shifts in the right, posterior and inferior directions worsen the plan dosimetry, nevertheless not negligible lung ∆ V20 of + 2.6%, and heart ∆ V25 of + 1.6% persist for 3 mm shifts. Conclusions Inaccuracy in isocenter positioning for VMAT left-sided PMRT irradiation may impact the dosimetry of the CTVs and OARs to a different extent, depending on the directions and magnitude of the perturbation. The acquired information could be useful for planning strategies to guarantee the accuracy of the treatment delivered.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.